Moderna administers for the first time the experimental cancer vaccine mRNA-4200, which is designed to stimulate the body to produce seven undisclosed tumour proteins

Open questions remain regarding long-term expression, the transfer of vaccine components to other people via exosomes and extracellular vesicles, and what is communicated to participants prior to participation

Moderna announced that it had administered an injection to the first participant in a Phase 1 clinical trial of mRNA-4200 (NCT06880549). This is an experimental mRNA product that, upon administration, prompts the body to produce seven unspecified tumour proteins.

In other words, the product does not simply supply the body with tumour proteins – it uses the body itself to produce them.

Intentionally.

The study raises obvious questions about safety and informed consent: How long does the body produce the allegedly encoded tumour proteins, what long-term biological effects could they have, and whether the product or its metabolites could be transferred from the original recipient to others via exosomes or extracellular vesicles in excreted body fluids.

A 2021 study in the Journal of Extracellular Vesicles found that cells expressing a target protein can release extracellular vesicles that “transport” that protein, showing that what is produced in the body can be transported out of the cell in membrane-bound particles.

A separate review article from 2023 in Pharmaceutics explains that exosomes are natural transport vesicles that carry proteins and nucleic acids throughout the body and are found in body fluids such as blood, saliva, and other secretions – meaning that they are not restricted to the original cell or even the original location in the body.

You can contact Moderna here and the FDA here.

The company states that it is investigating the product in patients with advanced solid tumours, including melanoma, non-small cell lung cancer, oesophageal cancer, stomach cancer, ovarian cancer, cervical cancer, endometrial cancer, bladder cancer and colon cancer.

Participants receive the injections either alone or in combination with pembrolizumab, a monoclonal antibody marketed under the name Keytruda.

In contrast to Moderna’s “personalized” cancer vaccine programs, which are supposedly tailored to the tumour characteristics of the patient, mRNA-4200 is described as a “standard product” intended for use in a variety of cancers.

According to Moderna’s public statements, the product works by delivering mRNA instructions after injection that lead to the production of seven common tumour proteins in the body.

The press release states:

“Moderna, Inc. (NASDAQ:MRNA) announced that the first U.S. participant in its Phase 1 trial evaluating mRNA-4200, a tumour-targeted cancer antigen therapy candidate, received its first dose in patients with advanced or metastatic solid tumours. mRNA-4200 encodes seven antigens commonly found together in patients and tumour types and is designed to help induce and enhance T-cell responses against selected tumour targets.”

However, Moderna has not publicly disclosed the identity of these proteins.

Therefore, we are currently unable to independently assess which proteins are produced, whether they are complete proteins or fragments, whether they occur in other parts of the body, or what biological effects might be associated with their expression.

The study is expected to involve approximately 42 participants; it will be conducted at sites in Michigan, Texas, and Utah.

Other cancer drugs from Moderna have encoded immune signalling proteins such as OX40L, IL-23 and IL-36γ and have also been combined with monoclonal antibodies that target immune checkpoint signalling pathways.

Conclusion

An experimental product that causes the body to produce tumour proteins within itself has now entered the phase of human trials.

No proteins administered from an ampoule.

No proteins that are manufactured in a laboratory.

Proteins that are produced in the recipient’s own body.

Intentionally.

Moderna states that there are seven of them.

The company has not publicly disclosed which ones.

This raises questions that should actually be self-evident.

• What occurs when the body is instructed to produce tumour proteins over a prolonged period of time?
• How long will they be produced?
• Where are they produced?
• What occurs when these proteins are expressed in tissues outside their intended target locations?
• And if proteins and nucleic acids produced in the body can be transported via extracellular vesicles and exosomes, which are present in all bodily fluids – what does informed consent look like for the people receiving the injections – and for everyone around them?

These are not trivial questions.

These are the first questions that should be answered before people are turned into production sites for undisclosed tumour proteins.

 

yogaesoteric
July 21, 2026